Vectura enters new development and licence agreement for a US inhaled generic
Agreement concerns an existing inhaled combination therapy for asthma and COPD delivered using a pMDI.
Vectura Group's subsidiary, Jagotec AG (collectively, "Vectura", "the Group"), has signed an exclusive development and licence agreement with Sandoz for the development of a generic of an existing major inhaled combination therapy for asthma and COPD in the US (VR2081) delivered using a pressurised metered dose inhaler (pMDI).
Under the terms of this agreement, Vectura is responsible for the development of the formulation and manufacture of clinical batches for use in pilot clinical studies whereas Sandoz is responsible for the clinical development, manufacture and commercialisation of VR2081.
Vectura will receive an initial payment of $5 million from Sandoz and is eligible to receive up to a further $5 million upon achievement of pre-determined development milestones. The Group is also eligible to receive a double digit percentage royalty on net sales in line with our other generic development programmes. The total R&D cost borne by Vectura is expected to be below $20 million up to regulatory filing and subsequent launch, which is anticipated in the early to mid-2020's. It is expected that the $5 million initial milestone will be recognised in revenues across 2017 and 2018 but will be offset by a modest increase in R&D spend in those years. The overall R&D guidance range of £65 million - £75 million for each of 2017 and 2018 remains unchanged.
The global respiratory market, worth over $40 billion in 2015, is expected to continue to grow, with current estimates predicting low single digit percentage growth annually up to 2025. Within this, the dynamics of the classes of products are forecast to change significantly with further generic penetration of core classes such as ICS/LABA and LAMA expected to gain momentum. The generics market is growing and accounts for over 80% of all US prescriptions and in 2015 was estimated to be worth c. $80 billion.
James Ward-Lilley, CEO, commented: "This agreement, extending our existing strong relationship with Sandoz, further reinforces Vectura's compelling position as a leader in the development of inhaled novel and generic products leveraging our suite of formulation and device platforms and proven development capabilities. Following the merger of Vectura and Skyepharma last summer we announced that we were prioritising three to five generic projects utilising the Group's newly combined pMDI and DPI device platforms. This programme represents the first partnered collaboration of this series of projects and offers substantial potential for future value creation."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance